Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Bruton's Tyrosine Kinase ( BTK ) Is a Novel KMT2A Partner Gene

Elena Zerkalenkova, PhD, Svetlana Lebedeva, Olga Soldatkina, Michael Maschan, MD PhD, Alexey A. Maschan, MD, Galina Novichkova, MD PhD, Yulia Olshanskaya, MD PhD

Blood (2019) 134 (Supplement_1): 5192.

https://doi.org/10.1182/blood-2019-128056

Published: 2019

Journal Articles

Utility of Newborn Screening for Severe Combined Immunodeficiency and X-Linked Agammaglobulinemia Using TREC and KREC Assays

Manabu Wakamatsu, MD, Hideki Muramatsu, MD PhD, Shinsuke Kataoka, MD, Yusuke Okuno, MD PhD, Sakai Yoshimi, Yoko Nakajima, MD PhD, Tetsuya Ito, MD PhD, Ikuya Tsuge, MD PhD, Seiji Kojima, MD PhD, Yoshiyuki Takahashi, MD PhD

Blood (2019) 134 (Supplement_1): 3604.

https://doi.org/10.1182/blood-2019-126669

Published: 2019

Journal Articles

Treatment for X-Linked Agammaglobulinemia with Allogeneic Umbilical Cord Blood Stem Cell Transplantation from HLA-Matched Sibling Confirmed Healthy through Prenatal Diagnosis

Dingming Wan, Ran Zhang, Meng Wang, Li Li, Weijie Cao, Suping Zhang, Kai Sun, MD, Xiaona Chen, Na Zhang

Blood (2018) 132 (Supplement 1): 5771.

https://doi.org/10.1182/blood-2018-99-116135

Published: 2018

Journal Articles

Inhibition of Btk Does Not Block Platelet Activation By GPVI: Studies with Ibrunitib, Acalabrutinib and Patients with X-Linked Agammaglobulinaemia

Phillip LR Nicolson, MA, MBBChir, MRCP, Stephanie Watson, BSc, Craig E Hughes, BSc, PhD, Alexander T Hardy, BSc, Callum N Watson, BSc, Samantha J Montague, BSc, PhD, Michael G Tomlinson, BSc, PhD, Guy Pratt, MD FRCP, FRCPath, Steve P Watson, PhD

Blood (2017) 130 (Supplement 1): 1030.

https://doi.org/10.1182/blood.V130.Suppl_1.1030.1030

Published: 2017

Journal Articles

Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy

Jeffrey A. Jones, MD, Peter Hillmen, MB, ChB, PhD, Steven Coutre, MD, Constantine Tam, MD, Richard R. Furman, MD, Paul M. Barr, MD, Stephen J. Schuster, MD, Thomas J. Kipps, MD, Ian W. Flinn, MD, Ulrich Jaeger, MD, Jan A. Burger, MD PhD, Mei Cheng, PhD, Dana Lee, PharmD, Danelle F. James, MD MAS, John C. Byrd, MD, Susan O'Brien, MD

Blood (2014) 124 (21): 1990.

https://doi.org/10.1182/blood.V124.21.1990.1990

Published: 2014

Journal Articles

In Patients With Chronic Lymphocytic Leukemia (CLL) Ibrutinib Effectively Reduces Clonal IgM Paraproteins and Serum Free Light Chains While Increasing Normal IgM, IgA Serum Levels, Suggesting a Nascent Recovery Of Humoral Immunity

Georg Aue, MD, Mohammed Farooqui, DO, Jade Jones, Janet Valdez, PA, Sabrina E. Martyr, MD, Susan Soto, RN, Maryalice Stetler-Stevenson, MD, PhD, Constance Yuan, MD, PhD, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 4182.

https://doi.org/10.1182/blood.V122.21.4182.4182

Published: 2013

Journal Articles

A Novel Bruton′s Tyrosine Kinase Inhibitor CC-292 In Combination With The Proteasome Inhibitor Carfilzomib Iimpacts Multiple Myeloma Bone Microenviroment With Resultant Anti-Myeloma Activity

Homare Eda, Loredana Santo, Diana D Cirstea, Andrew J Yee, Tyler A Scullen, Neeharika Nemani, Yuko Mishima, Shirin Arastu-Kapur, Erica Evans, Juswinder Singh, Christopher J Kirk, William F Westlin, Noopur S Raje

Blood (2013) 122 (21): 682.

https://doi.org/10.1182/blood.V122.21.682.682

Published: 2013

Journal Articles

Activity of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) in B-Cell Acute Lymphoblastic Leukemia (B-ALL).

Ekaterina Kim, MS, Stefan Koehrer, MD, Nathalie Y Rosin, PhD, Deborah A. Thomas, MD, Farhad Ravandi, MD, Steven M. Kornblau, MD, PhD, Hagop M. Kantarjian, MD, Susan O'Brien, MD, Zeev Estrov, MD, PhD, Joseph J. Buggy, PhD, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 2569.

https://doi.org/10.1182/blood.V120.21.2569.2569

Published: 2012

Journal Articles

AVL-292, a Bruton's Tyrosine Kinase Inhibitor Impacts Bone Resorption by Abrogating Osteoclast Sealing Zone Formation in Multiple Myeloma

Homare Eda, Loredana Santo, Diana Cirstea, Andrew J. Yee, Anuj Mahindra, Tyler Scullen, Neeharika Nemani, Yuko Mishima, Erica Evans, Juswinder Singh, Wes Westlin, Noopur Raje

Blood (2012) 120 (21): 1822.

https://doi.org/10.1182/blood.V120.21.1822.1822

Published: 2012

Journal Articles

Neonatal screening for severe primary immunodeficiency diseases using high-throughput triplex real-time PCR

Stephan Borte, Ulrika von Döbeln, Anders Fasth, Ning Wang, Magdalena Janzi, Jacek Winiarski, Ulrich Sack, Qiang Pan-Hammarström, Michael Borte, Lennart Hammarström

Blood (2012) 119 (11): 2552–2555.

https://doi.org/10.1182/blood-2011-08-371021

Published: 2012

Includes: Supplemental data

Journal Articles

Btk is a positive regulator in the TREM-1/DAP12 signaling pathway

Tereza Ormsby, Eva Schlecker, Janina Ferdin, Anja Sibylle Tessarz, Pavla Angelisová, Afitap Derya Köprülü, Michael Borte, Klaus Warnatz, Ilka Schulze, Wilfried Ellmeier, Václav Hořejší, Adelheid Cerwenka

Blood (2011) 118 (4): 936–945.

https://doi.org/10.1182/blood-2010-11-317016

Published: 2011

Includes: Supplemental data

Journal Articles

Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia

Katja Fiedler, Anca Sindrilaru, Grzegorz Terszowski, Enikö Kokai, Thorsten B. Feyerabend, Lars Bullinger, Hans-Reimer Rodewald, Cornelia Brunner

Blood (2011) 117 (4): 1329–1339.

https://doi.org/10.1182/blood-2010-04-281170

Published: 2011

Includes: Supplemental data

Journal Articles

Bruton's Tyrosine Kinase Inhibitor PCI-32765 Abrogates BCR- and Nurselike Cell-Derived Activation of CLL Cells In Vitro and In Vivo.

Sabine Ponader, PhD, Joseph Buggy, PhD, Susan O'Brien, BA, MD, William G. Wierda, MD, PhD, Michael Keating, MD, Jan A. Burger, MD, PhD

Blood (2010) 116 (21): 45.

https://doi.org/10.1182/blood.V116.21.45.45

Published: 2010

Journal Articles

B cell–specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia

Hannah M. Kerns, Byoung Y. Ryu, Brigid V. Stirling, Blythe D. Sather, Alexander Astrakhan, Stephanie Humblet-Baron, Denny Liggitt, David J. Rawlings

Blood (2010) 115 (11): 2146–2155.

https://doi.org/10.1182/blood-2009-09-241869

Published: 2010

Includes: Supplemental data

Journal Articles

A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay.

Daniel A Pollyea, MD, Sonali Smith, MD, Nathan Fowler, MD, Thomas E Boyd, MD, Ashley M Smith, BA, Mint Sirisawad, BS, Lee A Honigberg, PhD, Ahmed Hamdy, MD, Ranjana Advani, MD

Blood (2009) 114 (22): 3713.

https://doi.org/10.1182/blood.V114.22.3713.3713

Published: 2009

Journal Articles

Identification of MicroRNA Markers of Sensitivity to the Novel Bruton’s Tyrosine Kinase (BTK) Inhibitor PCI-32765 in Non-Hodgkin’s Lymphoma.

Sriram Balasubramanian, PhD, Jun Chen, Ph.D., Lee Honigberg, Ph.D., Lillian Tee, Hannah Mamuszka

Blood (2008) 112 (11): 3366.

https://doi.org/10.1182/blood.V112.11.3366.3366

Published: 2008

Journal Articles

Targeting Btk in Lymphoma: PCI-32765 Inhibits Tumor Growth in Mouse Lymphoma Models and a Fluorescent Analog of PCI-32765 Is an Active-Site Probe That Enables Assessment of Btk Inhibition In Vivo .

Lee A. Honigberg, PhD, Ashley M. Smith, B.S., Jun Chen, Ph.D., Patti Thiemann, B.S., Erik Verner, Ph.D.

Blood (2007) 110 (11): 1592.

https://doi.org/10.1182/blood.V110.11.1592.1592

Published: 2007

Journal Articles

Bruton’s Tyrosine Kinase (BTK) Is Not Required for BCR-ABL-Mediated Transformation of Hematopoietic Cells.

Mary MacPartlin, PhD, Lee A. Honigberg, Ph.D, Brian J. Druker, MD, Michael W. Deininger, MD, Ph.D

Blood (2007) 110 (11): 1015.

https://doi.org/10.1182/blood.V110.11.1015.1015

Published: 2007

Journal Articles

Expression of Bruton’s Tyrosine Kinase in Multiple Myeloma.

Guangbiao Zhou, MD, PhD, Ying Liu, Bo Zhang, Fanyi Meng, Xiaoli Liu, Ph.D

Blood (2007) 110 (11): 4751.

https://doi.org/10.1182/blood.V110.11.4751.4751

Published: 2007

Journal Articles

Impaired Toll-like receptor 8–mediated IL-6 and TNF-α production in antigen-presenting cells from patients with X-linked agammaglobulinemia

Klára Sochorová, Rudolf Horváth, Daniela Rožková, Jiří Litzman, Jiřina Bartůňková, Anna Šedivá, Radek Špíšek

Blood (2006) 109 (6): 2553–2556.

https://doi.org/10.1182/blood-2006-07-037960

Published: 2006

Includes: Supplemental data

NARROW

Bruton's Tyrosine Kinase ( BTK ) Is a Novel KMT2A Partner Gene

Utility of Newborn Screening for Severe Combined Immunodeficiency and X-Linked Agammaglobulinemia Using TREC and KREC Assays

Treatment for X-Linked Agammaglobulinemia with Allogeneic Umbilical Cord Blood Stem Cell Transplantation from HLA-Matched Sibling Confirmed Healthy through Prenatal Diagnosis

Inhibition of Btk Does Not Block Platelet Activation By GPVI: Studies with Ibrunitib, Acalabrutinib and Patients with X-Linked Agammaglobulinaemia

Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy

In Patients With Chronic Lymphocytic Leukemia (CLL) Ibrutinib Effectively Reduces Clonal IgM Paraproteins and Serum Free Light Chains While Increasing Normal IgM, IgA Serum Levels, Suggesting a Nascent Recovery Of Humoral Immunity

A Novel Bruton′s Tyrosine Kinase Inhibitor CC-292 In Combination With The Proteasome Inhibitor Carfilzomib Iimpacts Multiple Myeloma Bone Microenviroment With Resultant Anti-Myeloma Activity

Activity of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) in B-Cell Acute Lymphoblastic Leukemia (B-ALL).

AVL-292, a Bruton's Tyrosine Kinase Inhibitor Impacts Bone Resorption by Abrogating Osteoclast Sealing Zone Formation in Multiple Myeloma

Neonatal screening for severe primary immunodeficiency diseases using high-throughput triplex real-time PCR

Btk is a positive regulator in the TREM-1/DAP12 signaling pathway

Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia

Bruton's Tyrosine Kinase Inhibitor PCI-32765 Abrogates BCR- and Nurselike Cell-Derived Activation of CLL Cells In Vitro and In Vivo.

B cell–specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia

A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay.

Identification of MicroRNA Markers of Sensitivity to the Novel Bruton’s Tyrosine Kinase (BTK) Inhibitor PCI-32765 in Non-Hodgkin’s Lymphoma.

Targeting Btk in Lymphoma: PCI-32765 Inhibits Tumor Growth in Mouse Lymphoma Models and a Fluorescent Analog of PCI-32765 Is an Active-Site Probe That Enables Assessment of Btk Inhibition In Vivo .

Bruton’s Tyrosine Kinase (BTK) Is Not Required for BCR-ABL-Mediated Transformation of Hematopoietic Cells.

Expression of Bruton’s Tyrosine Kinase in Multiple Myeloma.

Impaired Toll-like receptor 8–mediated IL-6 and TNF-α production in antigen-presenting cells from patients with X-linked agammaglobulinemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only